EUVIMEDEUVIMED entdecken
Leitlinie

European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma

Alberto Papi iD, Diogenes S Ferreira iD, Ioana Agache, Eugenio Baraldi iD, Richard Beasley iD, Guy Brusselle iD, Courtney Coleman iD, Mina Gaga iD, Carolina Maria Gotera Rivera, Erik Melén iD, Ian D Pavord iD, Deborah Peñate Gómez und 4 weitere

European Respiratory Journal · 2023

DOI: 10.1183/13993003.00047-2023 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Alberto Papi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine, University of Ferrara, Ferrara, Italy ppa@unife.it. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent clinical trials of as-needed fixed-dose combination of inhaled corticosteroid (ICS)/formoterol have provided new evidence that may warrant a reconsideration of current practice. A Task Force was set up by the European Respiratory Society to provide evidence-based recommendations on the use of as-needed ICS/formoterol as treatment for mild asthma. The Task Force defined two questions that were assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The Task Force utilised the outcomes to develop recommendations for a pragmatic guideline for everyday clinical practice. The Task Force suggests that adults with mild asthma use as-needed ICS/formoterol instead of regular ICS maintenance treatment plus as-needed short-acting β 2 -antagonist (SABA) and that adolescents with mild asthma use either as-needed ICS/formoterol or ICS maintenance treatment plus as-needed SABA (conditional recommendation; low certainty of evidence). The recommendation for adults places a relatively higher value on the reduction of systemic corticosteroid use and the outcomes related to exacerbations, and a relatively lower value on the small differences in asthma control. Either treatment option is suggested for adolescent patients as the balance is very close and data more limited. The Task Force recommends that adult and adolescent patients with mild asthma use as-needed ICS/formoterol instead of as-needed SABA (strong recommendation; low certainty of evidence). This recommendation is based on the benefit of as-needed ICS/formoterol in mild asthma on several outcomes and the risks related to as-needed SABA in the absence of anti-inflammatory treatment. The implementation of this recommendation is hampered in countries (including European Union countries) where as-needed ICS/formoterol is not approved for mild asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaAdultAdolescentHumansFormoterol FumarateAdrenal Cortex HormonesAdministration, InhalationBudesonide

Substanzen

Formoterol FumarateAnti-Asthmatic AgentsAdrenal Cortex HormonesBudesonide

Autor:innen und Institutionen

  • Respiratory Medicine, University of Ferrara, Ferrara, Italy ppa@unife.it.
  • A. Papi and D.S. Ferreira contributed equally to this work.
  • A. Papi, D.S. Ferreira and F. Schleich are Task Force co-chairs.
  • Private Practice, Allergy and Immunology, Belo Horizonte, Brazil.
  • Faculty of Medicine, Transylvania University, Brasov, Romania.
  • Department of Women's and Children's Health, University of Padova, Institute of Pediatric Research "Città della Speranza", Padova, Italy.

ORCID-Profile: Alberto Papi, Diogenes S Ferreira, Eugenio Baraldi, Richard Beasley, Guy Brusselle, Courtney Coleman, Mina Gaga, Erik Melén, Ian D Pavord, Daniel Schuermans, Florence Schleich

Zitieren

APA

Papi, A., Ferreira, D. S., Agache, I., Baraldi, E., Beasley, R., Brusselle, G., Coleman, C., Gaga, M., Gotera Rivera, C. M., Melén, E., Pavord, I. D., Peñate Gómez, D., Schuermans, D., Spanevello, A., Tonia, T., & Schleich, F. (2023). European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma. European Respiratory Journal. https://doi.org/10.1183/13993003.00047-2023

Vancouver

Papi A, Ferreira DS, Agache I, Baraldi E, Beasley R, Brusselle G, et al. European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma. European Respiratory Journal. 2023. doi:10.1183/13993003.00047-2023

BibTeX
@article{Papi2023,
  author = {Papi, Alberto and Ferreira, Diogenes S and Agache, Ioana and Baraldi, Eugenio and Beasley, Richard and Brusselle, Guy and Coleman, Courtney and Gaga, Mina and Gotera Rivera, Carolina Maria and Melén, Erik and Pavord, Ian D and Peñate Gómez, Deborah and Schuermans, Daniel and Spanevello, Antonio and Tonia, Thomy and Schleich, Florence},
  title = {European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.00047-2023}
}
Kostenlos starten →